

1 **Integration of multi-omics data improves prediction of cervicovaginal microenvironment**
2 **in cervical cancer**

3

4 Nicholas A. Bokulich^{1,*}, Paweł Łaniewski^{2,*}, Dana M. Chase³, J. Gregory Caporaso⁴, Melissa M.

5 Herbst-Kralovetz^{2,5,#}

6

7 Affiliations

8 1 Laboratory of Food Systems Biotechnology, Institute of Food, Nutrition, and Health, ETH

9 Zürich, Switzerland.

10 2 Department of Basic Medical Sciences, College of Medicine-Phoenix, University of Arizona,

11 Phoenix, AZ, USA.

12 3 Arizona Oncology, Phoenix, AZ, USA.

13 4 Center for Applied Microbiome Science, Pathogen and Microbiome Institute, Northern Arizona

14 University, Flagstaff, AZ, USA.

15 5 Department of Obstetrics and Gynecology, College of Medicine-Phoenix, University of

16 Arizona, Phoenix, AZ, USA.

17

18 * These authors contributed equally to this work.

19

20 # Correspondence:

21 Melissa M. Herbst-Kralovetz, Ph.D.

22 425 N. 5th St., Phoenix, AZ 85004, USA

23 Phone: (602) 827-2247

24 Fax: (602) 827-2127

25 Email: mherbst1@arizona.edu

26

27 **Abstract**

28 Emerging evidence suggests that a complex interplay between human papillomavirus (HPV),
29 microbiota, and the cervicovaginal microenvironment contribute to HPV persistence and
30 carcinogenesis. Integration of multiple omics datasets is predicted to provide unique insight into
31 HPV infection and cervical cancer progression. Cervicovaginal specimens were collected from a
32 cohort (n=100) of Arizonan women with cervical cancer, cervical dysplasia, as well as HPV-
33 positive and HPV-negative controls. Microbiome, immunoproteome and metabolome analyses
34 were performed using 16S rRNA gene sequencing, multiplex cytometric bead arrays, and liquid
35 chromatography-mass spectrometry, respectively. Multi-omics integration methods, including
36 neural networks (mmvec) and Random Forest supervised learning, were utilized to explore
37 potential interactions and develop predictive models. Our integrated bioinformatic analyses
38 revealed that cancer biomarker concentrations were reliably predicted by Random Forest
39 regressors trained on microbiome and metabolome features, suggesting close correspondence
40 between the vaginal microbiome, metabolome, and genital inflammation involved in cervical
41 carcinogenesis. Furthermore, we show that features of the microbiome and host
42 microenvironment, including metabolites, microbial taxa, and immune biomarkers are predictive
43 of genital inflammation status, but only weakly to moderately predictive of cervical cancer state.
44 Different feature classes were important for prediction of different phenotypes. Lipids (e.g.
45 sphingolipids and long-chain unsaturated fatty acids) were strong predictors of genital
46 inflammation, whereas predictions of vaginal microbiota and vaginal pH relied mostly on
47 alterations in amino acid metabolism. Finally, we identified key immune biomarkers associated
48 with the vaginal microbiota composition and vaginal pH (MIF and TNF α), as well as genital
49 inflammation (IL-6, IL-10, leptin and VEGF). Integration of multiple different microbiome “omics”
50 data types resulted in modest increases in classifier performance over classifiers trained on the

51 best performing individual omics data type. However, since the most predictive features cannot
52 be known *a priori*, a multi-omics approach can still yield insights that might not be possible with
53 a single data type. Additionally, integrating multiple omics datasets provided insight into different
54 features of the cervicovaginal microenvironment and host response. Multi-omics is therefore
55 likely to remain essential for realizing the advances promised by microbiome research.

56 Running title: Multi-omics and cervicovaginal cancer microenvironment

57 Keywords: immunoproteome; metabolome; microbiome; HPV; cervical carcinogenesis; genital
58 inflammation; supervised learning

59

60

61 **Background**

62 Despite the availability of preventive measures, such as routine human papillomavirus
63 (HPV) vaccination and Pap smear screening, cervical cancer remains a major public health
64 problem, particularly in low- and middle-income countries, with approximately 570,000 new
65 cases and 311,000 deaths worldwide in 2018 (1). From an epidemiological standpoint, infection
66 with high-risk HPV types is a well-established risk factor for cervical cancer (2). Genital HPV
67 infection, although necessary, is not sufficient for development of precancerous cervical
68 dysplasia and progression to cancer (3), suggesting that other factors in the local cervicovaginal
69 microenvironment play a role during cervical carcinogenesis (4).

70 In the last two decades, the human microbiome (collectively the microbiota, or
71 communities of microorganisms residing in and on the human body, and their theatre of activity
72 (5) has emerged as a key regulator of mucosal homeostasis at various body sites, including the
73 female reproductive tract (6). The cervix and vagina in the majority of healthy, reproductive-age
74 women are colonized by one or few *Lactobacillus* species, primarily *L. crispatus*, *L. iners*, *L.*
75 *gasseri*, or *L. jensenii* (7). These beneficial microorganisms produce lactic acid (lowering vaginal
76 pH, typically below 4.5) and other antimicrobial metabolites, as well as block attachment of other
77 bacteria to the genital epithelium through competitive exclusion mechanisms. In addition,
78 *Lactobacillus* spp. stimulate the host to secrete physiological levels of cytokines, antimicrobial
79 peptides and metabolites (8).

80 Collectively, multifaceted interactions between *Lactobacillus* and the host create a
81 protective microenvironment against invading bacteria, fungi and viruses, including HPV (9).
82 However, during dysbiosis (disruption of the local microbial ecosystem, such as during disease)
83 protective *Lactobacillus* spp. are depleted and replaced by a diverse consortium of obligate and
84 strict anaerobes, resulting in elevated vaginal pH (10). These changes are associated with
85 increased risk for adverse gynecologic and reproductive outcomes, including sexually
86 transmitted infection (STI) acquisition (11). Indeed, several clinical studies have demonstrated

87 that HPV infection associates with substantial changes in the cervicovaginal microenvironment,
88 including shifts in microbial (12-28), metabolic (29, 30) and immunoproteomic profiles (17, 18,
89 31, 32), as well as vaginal pH levels (17), which might drive HPV persistence and/or disease
90 progression.

91 Multiple cross-sectional studies in various racial/ethnic cohorts consistently
92 demonstrated that women infected with HPV exhibit more diverse vaginal microbiota and
93 depleted levels of beneficial *Lactobacillus* spp. compared to HPV-negative women (12-15).
94 Women with cervical dysplasia or cancer also commonly lacked *Lactobacillus* dominance in
95 their vaginal microbiota (16-21). Furthermore, bacterial vaginosis (BV), which is a common
96 vaginal disorder characterized by a dramatic shift in microbiota composition from *Lactobacillus*
97 to anaerobes, has been linked to an increased risk of HPV acquisition and persistence (33-35).
98 Limited longitudinal studies also demonstrated that *Lactobacillus*-dominant microbiota correlates
99 with HPV clearance and regression of dysplasia, whereas depletion of *Lactobacillus* and
100 presence of specific anaerobic bacteria is associated with HPV and disease persistence (22-
101 25). Recent systematic reviews and meta-analyses of available studies supported a causal link
102 between dysbiotic vaginal microbiota and cervical cancer through the impact of bacteria on HPV
103 acquisition and persistence, as well as dysplasia development (26-28).

104 Metabolically, limited studies have reported that HPV infection and cervical dysplasia
105 relate to depletion of amino acid, peptide, and nucleotide signatures in the cervicovaginal
106 microenvironment (29, 30). Intriguingly, these metabolic alterations are also associated with
107 depletion of *Lactobacillus* spp., connecting HPV infection to vaginal dysbiosis (29, 36). In
108 contrast, cervical carcinoma profoundly perturbs lipid signatures, such as sphingomyelins (29),
109 which are also biomarkers of chronic inflammation (37) and associated with genital inflammation
110 (29).

111 In regard to host immune defenses, it is well documented that persistent HPV infection
112 suppresses immune responses, which may contribute to progression of HPV-mediated

113 neoplasm (38). Yet, the impact of the microbiome on host defenses across cervical
114 carcinogenesis has not been comprehensively studied. Recent studies have revealed that
115 dysbiotic non-*Lactobacillus* dominant microbiota are associated with elevated levels of pro-
116 inflammatory cytokines, growth and angiogenesis factors, apoptosis-related proteins, and
117 immune checkpoint proteins in the cervicovaginal fluids (17, 31, 32). Another cross-sectional
118 study suggested a link between dysbiotic fusobacteria and immunosuppressive host responses
119 (18). Taken together, these reports strongly implicate the complex interplay between HPV,
120 microbiota, and host response mechanisms in the local microenvironment in the progression of
121 (or protection from) neoplastic disease.

122 Here we present an integrated multi-omics analysis of clinical datasets including vaginal
123 microbiome (17), vaginal pH (17), metabolome (29) and immunoproteome (17, 31, 32), which
124 were previously generated using cervicovaginal specimens collected from a cohort ($n=100$) of
125 women with cervical cancer, cervical dysplasia, as well as HPV-positive and HPV-negative
126 controls, but which were previously analyzed independently. Cervical cancer disease
127 phenotypes emerge from the interactions between multiple features, including microbial taxa,
128 metabolic activity of microbes, host immune system activity, and the vaginal microenvironment.
129 Hence, we hypothesized that applying newly developed multi-omics integration techniques,
130 including microbe–metabolite vectors (mmvec (39)) neural networks and Random Forest
131 supervised learning models to delineate relationships between microbial, metabolic, and
132 proteomic signatures across a cervical carcinogenesis spectrum would allow us to learn more
133 from these data than we could from any single data type in isolation. We present new predictive
134 models of *Lactobacillus* dominance, vaginal pH, genital inflammation and cervical neoplastic
135 disease, and discuss the relative contribution of different features and feature types to our top-
136 performing models (**Figure 1**).

137 **Methods**

138 **Study population and clinical sample collection**

139 One hundred premenopausal, non-pregnant women were recruited at three clinical sites located
140 in Phoenix, AZ: St. Joseph's Hospital and Medical Center, University of Arizona Cancer Center
141 and Maricopa Integrated Health Systems. All participants provided informed written consent and
142 all research and related activities involving human subjects were approved by the Institutional
143 Review Boards at each participating site. The participants were grouped as follows: HPV-
144 negative controls [Ctrl HPV- ($n=20$)], HPV-positive controls [Ctrl HPV+ ($n=31$)], low grade
145 squamous intraepithelial lesions [LSIL ($n=12$)], high grade squamous intraepithelial lesions
146 [HSIL ($n=27$)] and invasive cervical carcinoma [ICC ($n=10$)]. Classification of patients into the
147 five groups and detailed exclusion criteria were described previously (Łaniewski et al., 2018).
148 Cervicovaginal lavage (CVL) and vaginal swabs were collected by a physician and processed
149 as described previously (17). Vaginal pH was measured using vaginal swabs, nitrazine paper
150 and a pH scale ranging from 4.5 to 7.5 (17). Demographic data was collected from surveys
151 and/or medical records.

152

153 **Immunoproteome analysis**

154 Levels of 73 protein targets were determined in CVL samples using multiplex cytometric bead
155 arrays or enzyme-linked immunosorbent assays and described previously (17, 31, 32). Briefly,
156 protein levels were measured using customized MILLIPLEX MAP® Human
157 Cytokine/Chemokine, Th17, High Sensitivity T Cell, Circulating Cancer Biomarker and Immuno-
158 Oncology Checkpoint Protein Magnetic Bead Panels (Millipore, Billerica, MA) or Human IL-36γ
159 ELISA kit (RayBiotech, Norcross, GA) in accordance with the manufacturer's protocol. Data
160 were collected with a Bio-Plex® 200 instrument and analyzed using Manager 5.0 software (Bio-
161 Rad, Hercules, CA). The genital inflammatory score system used in this study was described
162 previously (17). Briefly, levels of seven cytokines (IL-1α, IL-1β, IL-8, MIP-1β, MIP-3α, RANTES,

163 and TNF α) were used to determine inflammatory scores; patients were assigned one point for
164 each mediator when the level was in the upper quartile. Patients with inflammatory scores 5-7
165 were considered to have high genital inflammation, whereas patients with inflammatory scores
166 1-4 to have low genital inflammation. Patients with inflammatory score 0 were assigned to have
167 no genital inflammation.

168

169

170 **Metabolome analysis**

171 Global metabolome analysis was performed by Metabolon, Inc (Durham, NC) and described
172 previously (29). Briefly, a Waters ACQUITY ultra-performance liquid chromatography (UPLC)
173 and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with
174 a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at
175 35,000 mass resolution were utilized. Metabolites were identified and quantified using
176 Metabolon's Laboratory Information Management Systems (LIMS).

177

178 **Amplicon library preparation and sequencing for microbiome analysis**

179 DNA extraction and 16S rRNA gene sequencing were described previously (17). Briefly, DNA
180 was extracted from vaginal swabs using PowerSoil DNA Isolation Kit (MO BIO Laboratories,
181 Carlsbad, CA) following the manufacturer's instructions. Amplicon library preparation and
182 sequencing were performed by the Second Genome Inc. (San Francisco, CA). Briefly, the V4
183 region of bacterial 16S rRNA gene was amplified from the genomic DNA obtained from vaginal
184 swabs and sequenced on the MiSeq platform (Illumina, San Diego, CA).

185

186 **Bioinformatics analysis**

187 Microbial DNA sequence data were processed and analyzed using the plugin-based
188 microbiome bioinformatics framework QIIME 2 version 2019.7 (40). DADA2 (41) was used (via

189 the q2-dada2 QIIME 2 plugin) to quality filter the sequence data, removing PhiX, chimeric, and
190 erroneous reads, and merge paired-end reads. Forward and reverse reads were trimmed to 250
191 nt prior to denoising with dada2, otherwise default parameter settings were used. Taxonomy
192 was assigned to sequence variants using q2-feature-classifier (42) with the classify-sklearn
193 naive Bayes classification method against (1) the GreenGenes 16S rRNA reference database
194 13_8 release (43) assuming a uniform taxonomic distribution (44); (2) the Genome Taxonomy
195 Database (GTDB) (45), assuming a uniform taxonomic distribution; and (3) GTDB, with
196 taxonomic class weights (expected species distributions) assembled from a collection of 1,017
197 human cervicovaginal microbiota samples derived from the Vaginal Human Microbiome Project
198 (the same reference set used to construct the STIRRUPS database (46)) using q2-clawback
199 (44). RESCRIPT (<https://github.com/bokulich-lab/RESCRIPT>) (47) was used to merge these
200 taxonomies via determination of the last common ancestor (LCA) consensus taxonomy
201 assignment for each feature (giving priority to majority classifications, and using superstring
202 matching to facilitate compatibility between the Greengenes and GTDB taxonomies). Any
203 sequence that failed to classify at phylum level was discarded prior to downstream analysis.
204 Microbial feature tables were evenly sampled at 50,000 sequences per sample prior to
205 supervised classification.

206 Supervised learning was performed in q2-sample-classifier (48) via 10-fold nested cross-
207 validation (classify-samples-ncv method), using random forests classification or regression
208 models [<https://doi.org/10.1023/A:1010933404324>] grown with 500 trees. Receiver operating
209 characteristic (ROC) curves and area under the curve (AUC) analysis, confusion matrices, and
210 feature importance scores were generated as part of the q2-sample-classifier pipeline.

211 Supervised learning models were trained and tested using the following feature and target data:

- 212 1. Disease status was predicted using bacterial 16S rRNA gene ASV abundance,
213 metabolome, and immunoproteome data.

- 214 2. *Lactobacillus* dominance was predicted using metabolome and immunoproteome data.
215 *Lactobacillus* dominance categorization was based on the relative frequency of reads
216 classified to genus *Lactobacillus* via 16S rRNA gene sequencing; any sample with \geq
217 80% of reads classified as *Lactobacillus* were placed in the *Lactobacillus* dominant (LD)
218 group, and all other samples in the non-*Lactobacillus* dominant (NLD) group.
- 219 3. Vaginal pH was predicted using bacterial 16S rRNA gene ASV abundance, metabolome,
220 and immunoproteome data.
- 221 4. Genital inflammation scores were predicted using bacterial 16S rRNA gene ASV
222 abundance, metabolome, and immunoproteome data (excluding the 7 immunoproteome
223 markers that are used to calculate the inflammation score).
- 224 5. Immunoproteome markers (the abundance of each individual marker) was predicted
225 using metabolome and bacterial 16S rRNA gene ASV abundance data.
- 226 6. Metabolite abundance (the abundance of each individual metabolite) was predicted
227 using immunoproteome and bacterial 16S rRNA gene ASV abundance data.
- 228 AUC was calculated using scikit-learn (49) for each class, as well as micro- and macro-
229 averages. Micro-average is calculated across each sample, and hence impacted by class
230 imbalances. Macro-average gives equal weight to the classification of each sample, eliminating
231 the impact of class imbalances on average AUC.
- 232 Microbe-metabolite interactions were estimated using mmvec (39). This method uses
233 neural networks for estimating microbe-metabolite interactions through their co-occurrence
234 probabilities. Features with fewer than 10 observations were filtered prior to mmvec analysis.
235 Conditional rank probabilities were used to construct principal coordinate analysis biplots
236 (visualized using matplotlib [10.1109/MCSE.2007.55]) that illustrate the co-occurrence
237 probabilities of each metabolite and microbe.

238

239 **Results**

240 Interconnection of vaginal microbiome, metabolome, and immune biomarkers

241 Microbe-metabolite interactions were predicted using mmvec (39). This method uses neural
242 networks to estimate microbe-metabolite interactions through their co-occurrence probabilities.

243 This method predicted several strong microbe-metabolite associations. Numerous lipids

244 (including sphingolipids and long-chain unsaturated fatty acids) were associated with multiple

245 amplicon sequence variants (ASVs) belonging to *Prevotella* (including *Prevotella bivia*),

246 *Peptoniphilus*, *Streptococcus anginosus*, *Atopobium vaginae*, *Sneathia sanguinegenes*,

247 *Veillonellales*, *Finegoldia*, and other taxonomic groups (**Figure 2**). *Lactobacillus* ASVs

248 (*Lactobacillus crispatus*, *Lactobacillus iners*, *Lactobacillus_H*), as well as some *Prevotella*

249 (including *Prevotella bivia*), and other ASVs, were correlated with a range of metabolites

250 including phenylalanylglycine, the anti-inflammatory nucleotide cytosine,

251 glycerophosphoglycerol, glycerol, N-acetyl methionine sulfoxide, and maltopentaose (**Figure 2**).

252 These separations roughly mirror genital inflammation and disease status categories,

253 corresponding with our present findings (described below) as well as previous work showing

254 association between many of these lipids with ICC and high inflammation, and these non-lipid

255 metabolites with high *Lactobacillus* dominance and low inflammation (17, 29). Three-

256 hydroxybutyrate, previously associated with ICC (29), as well as piperolate, N-acetylcadaverine,

257 and deoxycarnitine were highly correlated with a range of *Streptococcus*, *Prevotella* (including

258 *Prevotella bivia*), *Megasphaera*, *Finegoldia*, *Atopobium vaginae*, *Sneathia amnii*, and *Sneathia*

259 *sanguinegens* ASVs. Interestingly, 3-hydroxybutyrate was also correlated to *Lactobacillus iners*.

260 To further dissect relationships among the metabolite, microbiome, and

261 immunoproteome, Random Forest regression with 10-fold cross-validation was used to

262 determine the ability to predict the abundance of individual metabolites based on microbiome

263 and immunoproteome profiles, revealing very strong predictive strength for a wide variety of

264 targets (**Supplementary Figure 1, Supplementary Table 1**). This includes the inflammation-
265 and ICC-associated lipids 1-palmitoyl-2-arachidonoyl-gpc (16:0/20:4), 1-palmitoyl-2-linoleoyl-
266 gpc (16:0/18:2), 1,2-dilinoleoyl-gpc (18:2/18:2), 1-palmitoyl-2-docosahexaenoyl-gpc (16:0/22:6),
267 several sphingomyelins, 1-stearoyl-2-docosahexaenoyl-gpc (18:0/22:6), 1-linoleoyl-2-
268 arachidonoyl-gpc (18:2/20:4n6), 1-palmitoyl-2-arachidonoyl-gpc (16:0/20:4n6), arachidonate,
269 and the bile acid glycochenodeoxycholate (**Supplementary Figure 1, Supplementary Table**
270 **1**). Many of these associations are driven by high abundances of these lipids, sphingomyelins,
271 and other metabolites in cancer cases: cancer biomarkers are the top predictive features for all
272 of these metabolites (**Supplementary Figure 2**), and when ICC cases are removed from the
273 dataset microbial features (including several *Sneathia*, *Atopobium*, *Prevotella*, *Fingoldia*, and
274 *Mobiluncus* ASVs) are included among the top predictive features, though high predictive
275 strength remains for many (but not all) of these targets (**Supplementary Figure 3-4**). The ability
276 to accurately predict the abundance of these metabolites through cross-validation highlights the
277 close correspondence between the metabolome, microbiome, and immunoproteome across
278 patients, both respective and irrespective of cancer diagnosis.

279 Random Forest regression was also performed to predict concentration of cancer
280 biomarkers based on microbiome and metabolome profiles, demonstrating strong predictive
281 strength for several targets, including proinflammatory cytokines and chemokines (IL-6, IL-8, IL-
282 36 γ , MIF, MIP-1 β), the anti-inflammatory cytokine IL-10, growth and angiogenic factors (HGF,
283 SCF, TGF- α), apoptosis-related proteins (sFAS, TRAIL), the hormone prolactin, the cytokeratin
284 CYFRA21-1, and other cancer biomarkers (AFP, sCD40L, CEA)) (**Supplementary Figure 5**).
285 Metabolites (primarily inflammation-associated lipids) are the most predictive features for each
286 of these targets, but microbial features occur among the top 15 predictive features for many of
287 these, most notably *Adlercreutzia* (*Eggerthellaceae*), *Megasphaera*, *Sneathia*, and *Parvimonas*
288 dominating the top important features for predicting cervicovaginal CEA concentration,
289 regardless of cancer diagnosis (**Supplementary Figure 6**). Several of these biomarkers are

290 clearly related to ICC, as indicated by reduced predictive strength after ICC cases are removed
291 from the dataset; however, most of these markers exhibit similar performance and important
292 feature associations after removing ICC cases (**Supplementary Figures 7-8**).

293 These findings indicate that both the metabolome and microbiome are highly correlated
294 with and predictive of cancer biomarker concentrations in the cervicovaginal mucosa. Hence,
295 metabolome and microbiome composition can be considered proxy measurements for genital
296 inflammation and immunological responses linked to cervicovaginal carcinogenesis, a
297 relationship that is more explicitly tested below.

298

299 **Metabolome and immunoproteome markers predict *Lactobacillus* dominance and vaginal** 300 **pH.**

301 We have previously demonstrated significant negative correlations between *Lactobacillus*
302 dominance (LD), genital inflammation, HPV infection, and ICC (17). Lactobacilli typically
303 dominate the cervicovaginal microbiota of healthy premenopausal women. However, in some
304 women, cervicovaginal microbiota lacks a high proportion of lactobacilli and consists of a
305 consortium of anaerobic bacteria. Intriguingly, Hispanic and black women more frequently
306 exhibit non-*Lactobacillus*-dominant (NLD) microbiota than white or Asian women, which might
307 relate to multiple socioeconomic, environmental and behavioral factors all of which may arise as
308 a result of structural racism (4). LD is associated with low genital inflammation and lower risk of
309 HPV acquisition, persistence and development of precancerous cervical dysplasia (26, 27).
310 Hence, we evaluated the ability of metabolome and immunoproteome features to predict LD, as
311 a proxy for their association with vaginal health in the Arizona-based cohort of women in this
312 study (comprising both non-Hispanic white women (NHW) and women of Hispanic origin). We
313 define LD as any sample in which *Lactobacillus* ASVs collectively comprise $\geq 80\%$ of the vaginal
314 microbiome, and grouped subjects into LD and NLD groups. We then predicted LD status based
315 on metabolome and immunoproteome profile using random forest classification with 10-fold

316 cross-validation. Microbiome data were excluded from the predictive model, as these
317 measurements are non-independent due to compositionality constraints, i.e., changing the
318 relative abundance of one feature (such as a *Lactobacillus* ASV) will alter the relative
319 abundance of other features.

320 Results demonstrate a very high predictive accuracy (average AUC = 0.94), indicating a
321 near-perfect ability to predict LD or NLD across subjects via cross-validation (**Figure 3A-B**). In
322 other words, cervicovaginal metabolome and immunoproteome profiles are tightly linked to the
323 abundance of *Lactobacillus* spp., suggesting that host immunological response is associated
324 with cervicovaginal microbiome composition. The top predictive features consist primarily of
325 non-lipid metabolites, consistent with the mmvec results (**Figure 2**), though the cancer
326 biomarkers macrophage migration inhibitory factor (MIF) and TNF α also rank among the top 50
327 most important predictive features (**Figure 3C**). Both MIF and TNF α are more abundant in NLD
328 women (**Supplementary Figure 9**), consistent with higher inflammation and ICC.

329 Vaginal pH is an important feature of the cervicovaginal microenvironment which relates
330 to *Lactobacillus* dominance. Briefly, vaginal *Lactobacillus* spp. utilize glycogen by-products in
331 the process of fermentation and produce lactic acid, which acidifies the local microenvironment
332 typically to pH below 4.5. This acidic microenvironment contributes to homeostasis and protects
333 the host against invading pathogens and pathobionts. We assessed the predictive relationship
334 between pH and cervicovaginal metabolites, microbiota, and immunoproteome using cross-
335 validated random forest classification models. For the purposes of this analysis, samples were
336 grouped into “low” (pH \leq 5.0) and “high” pH groups (pH $>$ 5.0). Lower vaginal pH is closely
337 related to demographic characteristics, and Hispanic women tend to have slightly higher
338 average vaginal pH compared to NHW (7, 17), hence we defined pH \leq 5.0 as “low” for the
339 purposes of this study. Results indicate a weak to moderate predictive relationship (AUC = 0.70)
340 (**Figure 4A**). Predictive power was lost because a large proportion (35.3%) of women with low
341 vaginal pH were predicted to belong to the high pH group (**Figure 4B**). This characteristic

342 merely indicates that 5.0 is not a reasonable cutoff for the purposes of this analysis; predicting
343 true vaginal pH using a regression model would be more appropriate to characterize the
344 numerical relationship between vaginal pH and the cervicovaginal environment but the small
345 sample size in the current study, strongly skewed toward lower pH values (**Supplementary**
346 **Figure 10**), prevented the use of cross-validated regression models to evaluate what is likely a
347 more integrative relationship than binary classification can achieve. Results also indicate that
348 this binary pH model, as expected, exhibits many of the same characteristics as the LD/NLD
349 prediction model: many of the same top predictive features were identified (**Figure 4C**). Notably,
350 the top predictive features consist primarily of non-lipid metabolites, and both MIF and TNF α are
351 again in the top 50 most important predictors, both associated with high pH as well as NLD
352 (**Supplementary Figures 9 and 11**). Hence, together these findings recapitulate the
353 associations between LD, low vaginal pH, and low inflammation, and between NLD, high pH,
354 higher inflammation, and carcinogenesis, as well as the microbial and metabolic context of
355 these states, explored in more detail below.

356

357 **Metabolome, immunoproteome, and microbiome accurately predict genital inflammation** 358 **but only moderately predict cancer status**

359 Next, we tested the relationship between the cervicovaginal environment and genital
360 inflammation, as a crucial characteristic of ICC progression. We have previously utilized a
361 scoring system to quantify genital inflammation in our cohort (17). To assign genital
362 inflammatory scores (0-7), levels of seven cytokines and chemokines, including IL-1 α , IL-1 β , IL-
363 8, MIP-1 β , MIP-3 α , RANTES, and TNF α , were measured in cervicovaginal lavages (CVL) and
364 patients were assigned a score based on whether the level of each immune mediator was in the
365 upper quartile. For the purposes of classification, subjects were grouped into no (score = 0), low
366 (0 < score < 5), or high inflammation (score \geq 5) groups, and random forest classifiers were
367 trained and tested via 10-fold cross-validation to assess the ability to predict genital

368 inflammation across subjects based on cervicovaginal microbiome, metabolome, and
369 immunoproteome (excluding the 7 inflammatory markers that are used to measure inflammatory
370 score). Results indicate moderately high predictive accuracy (macro-average AUC = 0.86)
371 (**Figure 5A**). Predictive accuracy is very good for high (AUC = 0.93) and no inflammation (AUC
372 = 0.90), but lowest for low inflammation (AUC = 0.75), due to misclassification of some samples
373 as either high or no inflammation (**Figure 5B**). Similar to pH classification but to a lesser extent,
374 this reflects the shortcoming of binning samples for classification into categorical groups, a
375 necessary limitation due to the small sample size of the current study. Regression models
376 predicting actual inflammation score demonstrate high accuracy at lower inflammation scores,
377 but lower accuracy at the upper range due to sparsity of high-inflammation samples for cross-
378 validation (**Supplemental Figure 12**). Larger sample sizes in future studies will enable more
379 accurate prediction of low-inflammation samples through prediction of actual inflammation
380 scores, refining our current estimates of associations between genital inflammation and
381 cervicovaginal microenvironment. As it stands, categorical classification performs moderately
382 well, and can identify a range of features predictive of inflammation, primarily lipids, but also
383 several immune mediators and cancer biomarkers including IL-10, MIP-1 α , IL-6, VEGF, and
384 leptin (**Figure 5C, Supplemental Figure 13**).

385 Given the ability to predict genital inflammation, a crucial feature of ICC progression,
386 based on features of the cervicovaginal microenvironment, we sought to determine if HPV
387 infection and carcinogenesis could also be predicted based on these features using cross-
388 validated random forest classification. Samples ($n=78$) were grouped into control HPV- ($n=18$),
389 control HPV+ ($n=11$), LSIL ($n=12$), HSIL ($n=27$), and ICC ($n=10$). This yielded low predictive
390 accuracy (micro-average AUC = 0.73, macro-average AUC = 0.64) (**Supplemental Figure 14**).
391 Although many of the same carcinogenesis-related metabolites and immune markers were top
392 predictors in these models (data not shown), accurate differentiation could not be achieved,
393 primarily because of the low sample size and large class imbalances, but also due to the large

394 number of classes with borderline differences (e.g., high similarity led to misclassification
395 between control HPV– and control HPV+ groups, and between LSIL and HSIL groups). Given
396 the low per-group sample sizes, approaches to mitigate class imbalances were not feasible in
397 the current study, but larger sample sizes and pooled analyses will facilitate better estimates in
398 future studies. However, it should be noted that ICC predictive accuracy was moderately high
399 (AUC = 0.79), in spite of the low sample size and class imbalance (**Supplemental Figure 14**).
400 This indicates that ICC could be predicted with fairly high accuracy across subjects, but non-ICC
401 groups could not be reliably distinguished due to the similarities between these groups.
402 Combining LSIL and HSIL prior to classification increases accuracy, indicating ambiguity
403 between these groups, as reflected in the imprecise distinction between these histological
404 classifications. Hence, ICC elicits signature characteristics in the cervicovaginal
405 microenvironment across subjects that can be used to identify these subjects, but intermediate
406 stages of progression (HPV infection, LSIL, HSIL) cannot be fully distinguished. Larger sample
407 sizes and longitudinal measurement in future studies may improve our ability to diagnose ICC or
408 even predict cancer risk based on cervicovaginal microenvironment characteristics
409 (metabolome, immunoproteome, microbiome).

410

411 **Discussion**

412 The vaginal microbiota, HPV infection and cervical neoplasm are related in ways that are still
413 not fully understood. Emerging evidence suggests that *Lactobacillus* dominance (LD) in the
414 vagina and cervix relates to HPV clearance and disease regression, whereas dysbiotic
415 anaerobes contribute to HPV persistence and progression of cervical neoplasm (26-28). Host
416 response to HPV and microbiota, which may result in genital inflammation, immune evasion,
417 and altered metabolism, likely contribute to establishment of persistent infection and disease
418 progression (29, 30, 50-53). Thus, improving our understanding of microbiota-virus-host
419 interactions in the local cervicovaginal microenvironment is imperative for the development of

420 novel diagnostic, preventative and therapeutic approaches, which might help reduce cervical
421 cancer burden among unvaccinated women in the future (54).

422 We investigated relationships between multiple clinical “omics” datasets (microbiome,
423 vaginal pH, metabolome, immunoproteome) collected from women (who had not been
424 vaccinated against HPV) across cervical carcinogenesis (**Fig. 1**). Using recently developed
425 integrated multi-omics bioinformatics tools, we aimed to establish predictive models and identify
426 key signatures related to vaginal microbiota structure, vaginal pH, genital inflammation and
427 cervical neoplasm status. We identified specific metabolites that were predictive of *Lactobacillus*
428 dominance, vaginal pH, and genital inflammation (**Fig. 3–5**). These findings demonstrate that
429 vaginal microbiota and host defense responses strongly influence cervicovaginal metabolic
430 fingerprints (29, 30, 55) and indicate that cervicovaginal metabolic signatures might be
431 promising biomarkers for gynecological conditions, including cervical cancer. In addition, select
432 immune mediators and cancer biomarkers also exhibited high importance scores in our
433 analyses for predictions of LD and vaginal pH (MIF and TNF α), as well as genital inflammation
434 (IL-6, IL-10, leptin, VEGF), further confirming the link between vaginal microbiota and host
435 immune responses (17, 31, 50, 56, 57). Intriguingly, microbial features did not rank among the
436 top predictors of vaginal pH or genital inflammation. Our neural network analyses and cross-
437 validated Random Forest classification models showed that the abundance of bacterial taxa
438 highly corresponded to levels of key metabolites, immune mediators, and cancer biomarkers
439 related to cervicovaginal health or dysbiosis (**Fig. 2**), suggesting tight coupling of the
440 microbiome, metabolome, and immunoproteome.

441 Using our approach, we were unable to accurately predict cervical neoplasm status, with
442 the exception of the cervical cancer group, which exhibited a moderate accuracy rate. Relatively
443 low samples size and imbalance in disease classification, which are limitations of our study,
444 might have impacted these predictions. Larger numbers of subjects as well as temporal data on
445 subjects will likely improve predictive models in the future, and better support causal links

446 between microbial dysbiosis and HPV-mediated carcinogenesis. In addition, pathophysiological
447 responses across the continuum of cervical neoplasm might not be uniform among patients with
448 different disease classifications (for example CIN1 and CIN2/3). Indeed, clinical studies have
449 shown contrasting results related to genital inflammation and cervical dysplasia. On one hand,
450 infection with high-risk HPV types or precancerous dysplasia has not been associated with
451 increased level of genital inflammation (17, 50, 53). On the other hand, one report showed
452 increased inflammatory cytokines in patients with cervical dysplasia, but it did not control for
453 microbiota composition (52). Despite not being able to predict disease status, our integrated
454 analyses revealed that we were able to better predict the cervicovaginal microenvironment
455 features.

456 Our integrated analyses revealed that different classes of metabolites are important for
457 prediction of different phenotypes: lipids were strong predictors of genital inflammation, while
458 amino acids, peptides and nucleotides were predictive of the vaginal microbiota composition.
459 Sphingolipids and long-chain unsaturated fatty acids in particular ranked as top predictors of
460 genital inflammation. Emerging studies have demonstrated that sphingolipids are implicated in
461 multiple pathological processes, such as inflammatory diseases, diabetes, and cancer (58). In a
462 previous report we showed that women with cervical cancer had elevated sphingolipids in the
463 cervicovaginal fluids, suggesting that cancer drives associations of phospholipids with
464 inflammation. However, we observed the correlation with inflammation even after excluding
465 cancer patients (29). In fact, sphingolipids are bioactive metabolites, which may mediate
466 inflammatory signaling through TNF α activation (37). Using neural network analysis, we also
467 showed the co-occurrence of many lipid metabolites and dysbiotic vaginal bacterial taxa
468 (including multiple BV-associated bacteria and *Streptococcus*), linking microbiota to
469 inflammatory markers.

470 Predictions of vaginal microbiota and vaginal pH relied mostly on alterations in amino
471 acid metabolism, which was in accordance with previous reports on cervicovaginal

472 metabolomes (30, 36, 55). Specifically we found that 3-hydroxybutyrate (β -hydroxybutyrate,
473 BHB), a ketone body, was strongly correlated with abundance of dysbiotic bacterial species,
474 such as *Streptococcus*, *Prevotella*, *Megasphaera*, *Atopobium* and *Sneathia*, and unexpectedly
475 with one of predominant vaginal *Lactobacillus* spp., *L. iners*. Notably, in a longitudinal clinical
476 study, *L. iners*-dominant vaginal microbiota has been shown to more often transition to dysbiotic
477 NLD microbiota compared to other *Lactobacillus* spp. (59). Furthermore, *L. iners* produces a
478 different ratio of lactic acid isoforms (60), which vary in bactericidal capacities (61); therefore,
479 the protective role of *L. iners* in the cervicovaginal microenvironment is still questionable (62).
480 We have previously demonstrated that 3-hydroxybutyrate (measured in the cervicovaginal
481 fluids) is an excellent discriminator of cervical cancer patients compared to healthy controls (29).
482 Several clinical studies also identified 3-hydroxybutyrate (but measured in serum or tissue
483 effusions) as a potential biomarker of other gynecologic malignancies, such as endometrial
484 cancer (63) and ovarian cancer (64, 65). Three-hydroxybutyrate has also been shown to
485 suppress activation of NLRP3 inflammasome (66). Thus, dysbiotic cervicovaginal bacteria and
486 *L. iners* might utilize this mechanism to evade host defense and, consequently, the
487 inflammasome deregulation might contribute to progression of cervical neoplasm (67).

488 Other key metabolites that we identify to highly correlate with dysbiotic microbiota were
489 piperolate and deoxycarnitine. In a previous study on metabolomes of women with BV, these
490 two metabolites positively associated with BV status and the presence of “clue cells” (vaginal
491 squamous epithelial cells covered with bacterial biofilm) (36), which is one of the clinical
492 characteristics of BV. In our report, we also revealed that deoxycarnitine in cervicovaginal fluids
493 can discriminate HPV-positive and HPV-negative women without neoplasia (29), linking vaginal
494 dysbiosis with HPV infection. With regard to the healthy vaginal microbiota, *Lactobacillus* spp.
495 (particularly *L. crispatus*) positively correlated with N-acetyl methionine sulfoxide, a reactive
496 oxygen species. Production of hydrogen peroxide, another reactive oxygen species, by vaginal
497 *Lactobacillus* spp. has been postulated to have a protective effect against invading pathogens

498 (68, 69). Similarly, an increase of N-acetyl methionine sulfoxide in the *Lactobacillus*-dominant
499 cervicovaginal microenvironment might contribute to host protection via oxidative stress.

500 Through our integrated multi-omics approach, we also identified key immune biomarkers
501 associated with the vaginal microbiota composition and vaginal pH, for instance MIF, a
502 pleiotropic cytokine regulating inflammatory reactions and stress responses (70). MIF was
503 identified as a top predictive factor of vaginal pH and LD in our Random Forest analysis, which
504 took into account multiple different “omics” data types (**Figures 3-4**), suggesting that
505 *Lactobacillus* colonization may be closely involved in regulating markers of genital inflammation,
506 including MIF. In accordance with our finding, several reports have demonstrated significantly
507 increased levels of MIF in cervicovaginal fluids of women with vaginal dysbiosis or BV
508 compared to women with healthy LD microbiota (57, 71, 72). In a previous report we identified
509 MIF (in cervicovaginal fluids) as a potential biomarker discriminating women with cervical cancer
510 from women with dysplasia and healthy controls (31). Other immunohistochemical studies
511 demonstrated overexpression of MIF cervical cancer tissues compared to healthy cervix and
512 dysplasia (73-75). Notably, MIF has been shown to promote cell proliferation, inhibit apoptosis
513 (74) and directly induce secretion of VEGF, an angiogenesis factor (73). Thus, elevated MIF
514 production induced by dysbiotic vaginal microbiota might contribute to cervical carcinogenesis.
515 Our integrated analysis further highlighted the importance of this key immune mediator, and
516 links its expression to vaginal microbiome and metabolome characteristics.

517 Another pro-inflammatory cytokine that strongly correlated with dysbiotic microbiota and
518 elevated pH was TNF α . Several clinical studies also demonstrated an increase of this cytokine
519 in cervicovaginal fluids of women with vaginal dysbiosis or BV (57, 71, 72, 76). Similar to MIF,
520 microbiota-induced TNF α might enhance cervical carcinogenesis, since this major inflammatory
521 cytokine has been shown to exhibit not only anti-tumor, but also pro-tumor bioactivities (77).
522 Interestingly, *in vitro* studies showed that only particular BV-associated species (for example,
523 *Atopobium vaginae* and *Mobiluncus mulieris*, but not *Prevotella bivia*) induce TNF α production

524 by genital epithelial cells (76, 78-80), suggesting species-specific roles of microbes within
525 dysbiotic polymicrobial consortia on host immunological response, which warrants further
526 investigations. Other immune mediators and cancer biomarkers (IL-6, IL-10, leptin and VEGF)
527 identified to be associated with genital inflammatory scores likely relate to cancer-induced
528 inflammation rather than a host defense response to dysbiotic vaginal microbiota (31). Overall,
529 our data indicate that mucosal inflammation is likely associated with cervical neoplasm via the
530 effect of vaginal microbiota on induction of specific inflammatory mediators and metabolites.

531

532 **Integrative omics increases predictive accuracy**

533 Many of the predictive models used in this study integrate multiple omics datasets: metabolome,
534 immunoproteome, and microbiome. We hypothesized that integrating multiple data types would
535 lead to a cumulative increase in predictive accuracy, as accumulating more features could help
536 refine the diagnostic signal of our random forests classifiers, different data types could yield
537 different signature characteristics for the prediction of different subject traits (e.g., inflammation,
538 disease state), and the combined signal could provide more subtle information to differentiate
539 particular groupings of subjects (e.g., LD versus non-LD, disease category). To address this
540 hypothesis directly, we evaluated the performance of each random forest classifier with different
541 combinations of omics data types with the expectation that more data types could only yield
542 better predictive accuracy.

543 Results indicate that integrating data led to modest increases in accuracy for most
544 classification tasks, but with mixed results (**Figure 6**). For LD, combining multiple datasets led to
545 very modest increases in accuracy (**Figure 6A**). Metabolites alone could predict LD status with
546 high accuracy; immunoproteome data exhibited much poorer accuracy, but combining both data
547 types yielded a slight increase in mean accuracy. For pH prediction, both metabolites and
548 microbiome datasets on their own could predict pH with moderate accuracy, but

549 immunoproteome could not; integrating all three omics datasets led to a slight increase in mean
550 accuracy (**Figure 6B**).

551 Genital inflammation was the one measurement that showed little change in accuracy
552 with integration of multiple omics datasets (**Figure 6C**). Both metabolome and immunoproteome
553 datasets yielded nearly identical high predictive accuracy, whereas microbiome data exhibited
554 poor predictive accuracy. Combining all three datasets led to no change in predictive accuracy.
555 Interestingly, for all tests combining datasets narrowed the variance in accuracy performance
556 (**Figure 6A-C**), suggesting that even if integrating multiple omic data types does not lead to
557 appreciably better accuracy, it could lead to improved reproducibility, but more investigation is
558 required to assess whether this performance enhancement is observed in other studies and
559 disease systems.

560

561 **Relevance of a multi-omics approach**

562 Given that we observed only a modest increase in classifier performance accuracy with the use
563 of multiple “omics” data types, it may seem that the benefit of including these additional data
564 does not justify their cost. However, it is important to note that we did not know, *a priori*, which
565 data type would provide the best predictive accuracy in this study. Furthermore, different
566 features types were differentially useful for predicting different features of the cervicovaginal
567 environment. Profiling different feature types therefore enabled discoveries that would not have
568 been possible had we focused only on a single feature type (e.g., the microbiome or the
569 metabolome).

570 Beginning to collect multi-omics data in human microbiome studies will enable a broader
571 understanding of the complex mechanistic interplay between microbes, metabolites, the host
572 immune system, and host phenotype. We suspect that this additional data will initially improve
573 our ability to make predictions about phenotype, as we have shown in this study. Inspection of
574 our machine learning models to discover important features enables us to develop hypotheses

575 about causation that can be prioritized for evaluation in future studies, and understanding which
576 feature types are most useful in predictive models can provide additional clues for
577 understanding the underlying biology. As our bioinformatics approaches for integrating multi-
578 omics data continue to improve, and as we continue to amass data relating microbes and
579 metabolites to the host immune system and phenotype, we will ultimately improve our ability to
580 model features (such as genital inflammation) based on combinations of microbes and
581 metabolites. This will enable design of treatments based on an understanding of, for example,
582 how the presence of a metabolite will impact the abundance of a group of microbes, which in
583 turn will drive or suppress an immune response.

584

585 **Conclusions**

586 There is much work to be done to improve our approaches for integrated multi-omics analyses.
587 For example, developing machine learning classification tools for microbiome multi-omics data
588 that can handle multiple observations per subject to make better use of longitudinal data, and
589 interactive visualization tools that can assist with exploration and interpretation of multi-omics
590 network data will facilitate work. Combining these approaches with novel methods (44) and
591 databases (46, 47) for accurate taxonomic classification of vaginal microbiota will further
592 advance our ability to identify microbial species linked to carcinogenesis and prevention. We
593 posit that integrated multi-omics approaches are essential to enabling many of the advances in
594 human medicine that are promised by microbiome research.

595

596 **List of abbreviations:**

597 ASV: amplicon sequencing variants

598 AUC: area under the curve

599 BV: bacterial vaginosis

600 CIN: cervical intraepithelial lesion

601 Ctrl: control
602 CVL: cervicovaginal lavage
603 HPV: human papillomavirus
604 HSIL: high grade squamous intraepithelial lesions
605 ICC: invasive cervical carcinoma
606 LD: *Lactobacillus* dominance
607 LSIL: low grade squamous intraepithelial lesions
608 NHW: non-Hispanic white
609 NLD: non-*Lactobacillus* dominance

610

611 **Declarations**

612 **Ethics approval and consent to participate**

613 All participants provided informed written consent and all research and related activities
614 involving human subjects were approved by the Institutional Review Boards at St. Joseph's
615 Hospital and Medical Center, University of Arizona Cancer Center and Maricopa Integrated
616 Health Systems, all located in Phoenix, AZ.

617

618 **Consent for publication**

619 Not applicable.

620

621 **Availability of data and materials**

622 Bacterial 16s RNA gene sequence data analyzed in this study were deposited in SRA
623 (PRJNA518153). Immunoproteome and metabolome data are available online as
624 supplementary materials accompanying our previous reports (17, 18, 31, 32).

625

626 **Competing interests**

627 Authors declare no competing interests.

628

629 **Funding**

630 This study was supported by the Flinn Foundation Grant #1974 to D.M.C. and M.M.H-K., Flinn

631 Foundation Grant #2244 to M.M.H-K. and the National Institutes of Health NCI awards for the

632 Partnership of Native American Cancer Prevention U54CA143924 (UACC) to M.M.H-K and

633 U54CA143925 (NAU) to G.J.C.

634

635 **Authors' contributions**

636 M.M.H.-K. and D.M.C conceived and designed the study. D.M.C. participated in the patient

637 recruitment and sample collection. P.Ł. processed the samples and performed the biological

638 assays. N.A.B. performed bioinformatic analyses. N.A.B., P.Ł., G.J.C. and M.M.H-K. analyzed

639 and interpreted the data. P.Ł and N.A.B. drafted the manuscript. M.M.H-K., G.J.C. and D.M.C.

640 critically reviewed the manuscript. All authors read and approved the final version of the paper.

641

642 **Acknowledgements**

643 We would like to thank the patients who enrolled in the study and acknowledge Kelli Williamson,

644 Ann De Jong, Eileen Molzen, Liane Fales, Maureen Sutton for the kind assistance in patient

645 recruitment and sample collection and Drs. Dominique Barnes and Alison Goulder for the

646 assistance with clinical sample and data collection.

647

648 **Figure legends**

649

650 **Figure 1. Schematic of a multi-omics approach to study the complex interplay between**

651 **HPV, host and microbiota in women across cervical neoplasia.** In this multicenter study

652 $n=100$ women were enrolled with invasive cervical carcinoma (ICC), high- and low-grade

653 squamous intraepithelial lesions (HSIL, LSIL), as well as, HPV-positive and healthy HPV-
654 negative controls (Ctrl). Vaginal swabs and cervicovaginal lavages (CVL) were collected for
655 vaginal pH, microbiome, metabolome and immunoproteome analyses. Patient-related metadata,
656 including age, body mass index (BMI), ethnicity, were also collected through medical records
657 and surveys. The vaginal microbiota compositions were determined by 16S rRNA gene
658 sequencing ($n=99$) revealing 849 amplicon sequencing variants (ASVs). Cervicovaginal
659 metabolic fingerprints were profiled by liquid chromatography-mass spectrometry ($n=78$) and
660 identified 475 unique metabolites. Levels of immune mediators ($n=100$) and other cancer-
661 related proteins ($n=78$) in CVL samples (73 targets) were evaluated using multiplex cytometric
662 bead arrays. Principal component, hierarchical clustering, neural network (mmvec) and Random
663 Forest analyses were utilized to explore associations among multi-omics data sets to predict
664 *Lactobacillus* dominance (dominant vs. non-dominant), vaginal pH (low ≤ 5 vs. high >5),
665 evidence of genital inflammation (high, low, none) and disease status (Ctrl HPV-, Ctrl HPV+,
666 LSIL, HSIL, ICC).

667
668 **Figure 2. Microbiome-metabolome interaction probabilities via mmvec predicts strong**
669 **associations between lipid metabolites with *Prevotella*, *Streptococcus*, *Atopobium*,**
670 ***Sneathia* and other clades [MH1] . A.** The principal component analysis (PCA) biplot displays
671 the top correlations, colored by genus (for microbial features) or by super pathway (for
672 metabolite features). The correlations were tested using mmvec. This method uses neural
673 networks for estimating microbe-metabolite interactions through their co-occurrence
674 probabilities[MH2]. Microbes (points) and metabolites (arrows) that appear closer to each other
675 in the biplot have a higher likelihood of co-occurring. **B.** The heatmap depicts the correlation
676 coefficients between ASVs and metabolites; hierarchical clustering was done via average
677 weighted Bray-Curtis distance. ASVs were determined using the consensus taxonomy (see
678 Methods section).

679

680 **Figure 3. Metabolites (particularly xenobiotics, carbohydrates, amino acids and**
681 **peptides) and the inflammatory cytokine MIF can accurately predict *Lactobacillus***
682 **dominance.** Integrated vaginal metabolome and immunoproteome profiles were used as
683 predictive features for training cross-validated Random Forest classifiers to predict whether a
684 subject's vaginal microbiota is *Lactobacillus* dominant (LD \geq 80% relative abundance consists of
685 *Lactobacillus* ASVs) or non-LD (NLD $<$ 80% relative abundance consists of lactobacilli).
686 Combined measurements predict the *Lactobacillus* dominance [MH3] at an overall accuracy
687 rate of 88.9%. A 1.6-fold improvement over baseline accuracy was observed. Receiver
688 operating characteristics (ROC) analysis showing true and false positive rates for each group,
689 indicating excellent predictive accuracy for both LD (AUC = 0.94) and NLD groups (AUC = 0.94)
690 (A). The confusion matrix illustrates the proportion of times each sample receives the correct
691 classification (B). The graphs depict the 25 most strongly predictive features ranked by relative
692 importance score, a measure of their contribution to classifier accuracy (C).

693

694 **Figure 4. Metabolites (particularly amino acids, peptides and nucleotides) and**
695 **inflammatory cytokine MIF are the best predictors of vaginal pH.** Integrated vaginal
696 microbiome, metabolome, and immunoproteome profiles were used as predictive features for
697 training cross-validated Random Forest classifiers to predict whether a subject's vaginal pH was
698 low (\leq 5.0) or high ($>$ 5.0). Combined measurements predict vaginal pH at an overall accuracy
699 rate of 72.6%. A 1.4-fold improvement over baseline accuracy was observed. Receiver
700 operating characteristics (ROC) analysis showing true and false positive rates for each group,
701 indicating weak predictive accuracy (micro-average AUC = 0.70) for both low (AUC = 0.70) and
702 high pH groups (AUC = 0.70) (A). The confusion matrix illustrates the proportion of times each
703 sample receives the correct classification (B). The graphs depict the 25 most strongly predictive

704 features ranked by relative importance score, a measure of their contribution to classifier
705 accuracy (C).

706

707 **Figure 5. Various metabolites (particularly long-chain fatty acids, sphingolipids and**
708 **glucose), inflammatory cytokines (IL-6, IL-10, MIP-1alpha) and cancer biomarkers (leptin,**
709 **VEGF) are the best predictors of the genital inflammation.** Integrated vaginal microbiome,
710 metabolome, and immunoproteome profiles (excluding the 7 cytokines used to score genital
711 inflammation) were used as predictive features for training cross-validated Random Forest
712 classifiers to predict whether a subject's genital inflammation score was "no inflammation" (0),
713 low (1-4), or high (≥ 5.0). Combined measurements predict inflammation score at an overall
714 accuracy rate of 75.3%. A 1.6-fold improvement over baseline accuracy was observed.

715 Receiver operating characteristics (ROC) analysis showing true and false positive rates for each
716 group, indicating moderate average accuracy (micro-average AUC = 0.88) and weak to good
717 predictive accuracy for each group (A). The confusion matrix illustrates the proportion of times
718 each sample receives the correct classification (B). The graphs depict the 25 most strongly
719 predictive features ranked by relative importance score, a measure of their contribution to
720 classifier accuracy (C).

721

722 **Figure 6. Integrating multiple -omics datasets does not dramatically improve overall**
723 **prediction accuracy; however, different integration of various measurements are needed**
724 **for the best prediction of distinct features.** Graphs show stepwise accuracy levels for
725 *Lactobacillus* dominance (A), vaginal pH (B) and genital inflammation (C) when random forest
726 models are trained on a single omics dataset or combined data containing 2-3 omics datasets.
727 *Lactobacillus* dominance can be explained mostly by metabolome data, vaginal pH by
728 metabolome and microbiome datasets, and genital inflammation by metabolome and
729 immunoproteome datasets. Combining omics datasets leads to slightly higher average accuracy

730 scores for *Lactobacillus* dominance and vaginal pH classification, but no effect on genital
731 inflammation classification.

732

733 **References**

- 734 1. Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, et al. Estimates of
735 incidence and mortality of cervical cancer in 2018: a worldwide analysis. *Lancet Glob Health*.
736 2020;8(2):e191-e203.
- 737 2. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human
738 papillomavirus and cervical cancer. *Lancet*. 2007;370(9590):890-907.
- 739 3. Gravitt PE, Winer RL. Natural history of HPV infection across the lifespan: role of viral
740 latency. *Viruses*. 2017;9(10).
- 741 4. Łaniewski P, Ilhan ZE, Herbst-Kralovetz MM. The microbiome and gynaecological
742 cancer development, prevention and therapy. *Nat Rev Urol*. 2020;17(4):232-50.
- 743 5. Berg G, Rybakova D, Fischer D, Cernava T, Verges MC, Charles T, et al. Microbiome
744 definition re-visited: old concepts and new challenges. *Microbiome*. 2020;8(1):103.
- 745 6. Integrative HMPRNC. The Integrative Human Microbiome Project. *Nature*.
746 2019;569(7758):641-8.
- 747 7. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal
748 microbiome of reproductive-age women. *Proc Natl Acad Sci U S A*. 2011;108 Suppl 1:4680-7.
- 749 8. Anahtar MN, Gootenberg DB, Mitchell CM, Kwon DS. Cervicovaginal microbiota and
750 reproductive health: The virtue of simplicity. *Cell host & microbe*. 2018;23(2):159-68.
- 751 9. Martin DH, Marrazzo JM. The vaginal microbiome: Current understanding and future
752 directions. *J Infect Dis*. 2016;214 Suppl 1:S36-41.
- 753 10. Onderdonk AB, Delaney ML, Fichorova RN. The human microbiome during bacterial
754 vaginosis. *Clin Microbiol Rev*. 2016;29(2):223-38.
- 755 11. Hillier SL, Marrazzo J, Holmes KK. Bacterial Vaginosis. In: Holmes KK, Sparling PF,
756 Stamm WE, Piot P, Wasserheit JN, Corey L, et al., editors. *Sexually Transmitted Diseases*,
757 Fourth Edition: McGraw-Hill Education; 2007. p. 737-68.
- 758 12. Lee JE, Lee S, Lee H, Song YM, Lee K, Han MJ, et al. Association of the vaginal
759 microbiota with human papillomavirus infection in a Korean twin cohort. *PLoS One*.
760 2013;8(5):e63514.
- 761 13. Chen Y, Hong Z, Wang W, Gu L, Gao H, Qiu L, et al. Association between the vaginal
762 microbiome and high-risk human papillomavirus infection in pregnant Chinese women. *BMC*
763 *Infect Dis*. 2019;19(1):677.
- 764 14. Gao W, Weng J, Gao Y, Chen X. Comparison of the vaginal microbiota diversity of
765 women with and without human papillomavirus infection: a cross-sectional study. *BMC Infect*
766 *Dis*. 2013;13:271.
- 767 15. Tuominen H, Rautava S, Syrjanen S, Collado MC, Rautava J. HPV infection and
768 bacterial microbiota in the placenta, uterine cervix and oral mucosa. *Sci Rep*. 2018;8(1):9787.
- 769 16. Mitra A, MacIntyre DA, Lee YS, Smith A, Marchesi JR, Lehne B, et al. Cervical
770 intraepithelial neoplasia disease progression is associated with increased vaginal microbiome
771 diversity. *Sci Rep*. 2015;5:16865.
- 772 17. Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM, et al. Linking
773 cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis
774 in non-Hispanic and Hispanic women. *Sci Rep*. 2018;8(1):7593.

- 775 18. Audirac-Chalifour A, Torres-Poveda K, Bahena-Roman M, Tellez-Sosa J, Martinez-
776 Barnette J, Cortina-Ceballos B, et al. Cervical microbiome and cytokine profile at various
777 stages of cervical cancer: a pilot study. *PLoS One*. 2016;11(4):e0153274.
- 778 19. Oh HY, Kim BS, Seo SS, Kong JS, Lee JK, Park SY, et al. The association of uterine
779 cervical microbiota with an increased risk for cervical intraepithelial neoplasia in Korea. *Clin*
780 *Microbiol Infect*. 2015;21(7):674 e1-9.
- 781 20. Kwasniewski W, Wolun-Cholewa M, Kotarski J, Warchol W, Kuzma D, Kwasniewska A,
782 et al. Microbiota dysbiosis is associated with HPV-induced cervical carcinogenesis. *Oncol Lett*.
783 2018;16(6):7035-47.
- 784 21. Godoy-Vitorino F, Romaguera J, Zhao C, Vargas-Robles D, Ortiz-Morales G, Vazquez-
785 Sanchez F, et al. Cervicovaginal fungi and bacteria associated with cervical intraepithelial
786 neoplasia and high-risk human papillomavirus infections in a Hispanic population. *Front*
787 *Microbiol*. 2018;9:2533.
- 788 22. Brotman RM, Shardell MD, Gajer P, Tracy JK, Zenilman JM, Ravel J, et al. Interplay
789 between the temporal dynamics of the vaginal microbiota and human papillomavirus detection.
790 *J Infect Dis*. 2014;210(11):1723-33.
- 791 23. Di Paola M, Sani C, Clemente AM, Iossa A, Perissi E, Castronovo G, et al.
792 Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human
793 Papillomavirus infection. *Sci Rep*. 2017;7(1):10200.
- 794 24. Mitra A, MacIntyre DA, Ntrisos G, Smith A, Tsilidis KK, Marchesi JR, et al. The vaginal
795 microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2
796 lesions. *Nat Commun*. 2020;11(1):1999.
- 797 25. Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, et al. Cervicovaginal
798 microbiome and natural history of HPV in a longitudinal study. *PLoS Pathog*.
799 2020;16(3):e1008376.
- 800 26. Norenhag J, Du J, Olovsson M, Verstraelen H, Engstrand L, Brusselaers N. The vaginal
801 microbiota, human papillomavirus and cervical dysplasia: a systematic review and network
802 meta-analysis. *BJOG*. 2020;127(2):171-80.
- 803 27. Wang H, Ma Y, Li R, Chen X, Wan L, Zhao W. Associations of cervicovaginal lactobacilli
804 with high-risk HPV infection, cervical intraepithelial neoplasia, and cancer: a systematic review
805 and meta-analysis. *J Infect Dis*. 2019.
- 806 28. Brusselaers N, Shrestha S, Van De Wijgert J, Verstraelen H. Vaginal dysbiosis, and the
807 risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. *Am J*
808 *Obstet Gynecol*. 2018.
- 809 29. Ilhan ZE, Łaniewski P, Thomas N, Roe DJ, Chase DM, Herbst-Kralovetz MM.
810 Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through
811 cervicovaginal metabolic profiling. *EBioMedicine*. 2019;44:675-90.
- 812 30. Borgogna JC, Shardell MD, Santori EK, Nelson TM, Rath JM, Glover ED, et al. The
813 vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women: a
814 cross-sectional analysis. *BJOG*. 2020;127(2):182-92.
- 815 31. Łaniewski P, Cui H, Roe DJ, Barnes D, Goulder A, Monk BJ, et al. Features of the
816 cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical
817 carcinogenesis. *Sci Rep*. 2019;9(1):7333.
- 818 32. Łaniewski P, Cui H, Roe DJ, Chase DM, Herbst-Kralovetz MM. Vaginal microbiota,
819 genital inflammation and neoplasia impact immune checkpoint protein profiles in the
820 cervicovaginal microenvironment. *NPJ Precis Oncol*. 2020.
- 821 33. Watts DH, Fazzari M, Minkoff H, Hillier SL, Sha B, Glesby M, et al. Effects of bacterial
822 vaginosis and other genital infections on the natural history of human papillomavirus infection in
823 HIV-1-infected and high-risk HIV-1-uninfected women. *J Infect Dis*. 2005;191(7):1129-39.

- 824 34. Gillet E, Meys JF, Verstraelen H, Bosire C, De Sutter P, Temmerman M, et al. Bacterial
825 vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis.
826 *BMC Infect Dis.* 2011;11:10.
- 827 35. Guo YL, You K, Qiao J, Zhao YM, Geng L. Bacterial vaginosis is conducive to the
828 persistence of HPV infection. *Int J STD AIDS.* 2012;23(8):581-4.
- 829 36. Srinivasan S, Morgan MT, Fiedler TL, Djukovic D, Hoffman NG, Raftery D, et al.
830 Metabolic signatures of bacterial vaginosis. *MBio.* 2015;6(2).
- 831 37. Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. *Nature.*
832 2014;510(7503):58-67.
- 833 38. Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human
834 papillomavirus. *Virus Res.* 2017;231:21-33.
- 835 39. Morton JT, Aksenov AA, Nothias LF, Foulds JR, Quinn RA, Badri MH, et al. Learning
836 representations of microbe-metabolite interactions. *Nat Methods.* 2019;16(12):1306-14.
- 837 40. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.
838 Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat*
839 *Biotechnol.* 2019;37(8):852-7.
- 840 41. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2:
841 High-resolution sample inference from Illumina amplicon data. *Nat Methods.* 2016;13(7):581-3.
- 842 42. Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, et al. Optimizing
843 taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-
844 classifier plugin. *Microbiome.* 2018;6(1):90.
- 845 43. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, et al. An
846 improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of
847 bacteria and archaea. *ISME J.* 2012;6(3):610-8.
- 848 44. Kaehler BD, Bokulich NA, McDonald D, Knight R, Caporaso JG, Huttley GA. Species
849 abundance information improves sequence taxonomy classification accuracy. *Nat Commun.*
850 2019;10(1):4643.
- 851 45. Parks DH, Chuvochina M, Waite DW, Rinke C, Skarshewski A, Chaumeil PA, et al. A
852 standardized bacterial taxonomy based on genome phylogeny substantially revises the tree of
853 life. *Nat Biotechnol.* 2018;36(10):996-1004.
- 854 46. Fettweis JM, Serrano MG, Sheth NU, Mayer CM, Glascock AL, Brooks JP, et al.
855 Species-level classification of the vaginal microbiome. *BMC Genomics.* 2012;13 Suppl 8:S17.
- 856 47. Nicholas Bokulich, Mike Robeson, Ben Kaehler, & Matthew Dillon. bokulich-
857 lab/RESCRIPt. Zenodo. <http://doi.org/10.5281/zenodo.3891931>
- 858 48. Bokulich NA, Dillon MR, Bolyen E, Kaehler BD, Huttley GA, Caporaso JG. q2-sample-
859 classifier: machine-learning tools for microbiome classification and regression. *J Open Res*
860 *Softw.* 2018;3(30).
- 861 49. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn:
862 Machine learning in Python. *J Mach Learn Res.* 2011;12:2825-30.
- 863 50. Shannon B, Yi TJ, Perusini S, Gajer P, Ma B, Humphrys MS, et al. Association of HPV
864 infection and clearance with cervicovaginal immunology and the vaginal microbiota. *Mucosal*
865 *Immunol.* 2017;10(5):1310-9.
- 866 51. Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, et al. An association
867 of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic
868 human papillomavirus (HPV). *Cancer Epidemiol Biomarkers Prev.* 2001;10(10):1021-7.
- 869 52. Mhatre M, McAndrew T, Carpenter C, Burk RD, Einstein MH, Herold BC. Cervical
870 intraepithelial neoplasia is associated with genital tract mucosal inflammation. *Sex Transm Dis.*
871 2012;39(8):591-7.
- 872 53. Kriek JM, Jaumdally SZ, Masson L, Little F, Mbulawa Z, Gumbi PP, et al. Female genital
873 tract inflammation, HIV co-infection and persistent mucosal Human Papillomavirus (HPV)
874 infections. *Virology.* 2016;493:247-54.

- 875 54. Drolet M, Benard E, Perez N, Brisson M, Group HPVVIS. Population-level impact and
876 herd effects following the introduction of human papillomavirus vaccination programmes:
877 updated systematic review and meta-analysis. *Lancet*. 2019;394(10197):497-509.
- 878 55. Nelson TM, Borgogna JC, Michalek RD, Roberts DW, Rath JM, Glover ED, et al.
879 Cigarette smoking is associated with an altered vaginal tract metabolomic profile. *Sci Rep*.
880 2018;8(1):852.
- 881 56. Masson L, Arnold KB, Little F, Mlisana K, Lewis DA, Mkhize N, et al. Inflammatory
882 cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and
883 bacterial vaginosis who are at high risk of HIV infection. *Sex Transm Infect*. 2016;92(3):186-93.
- 884 57. Lennard K, Dabee S, Barnabas SL, Havyarimana E, Blakney A, Jaumdally SZ, et al.
885 Microbial composition predicts genital tract inflammation and persistent bacterial vaginosis in
886 South African adolescent females. *Infect Immun*. 2018;86(1).
- 887 58. Gomez-Larrauri A, Presa N, Dominguez-Herrera A, Ouro A, Trueba M, Gomez-Munoz
888 A. Role of bioactive sphingolipids in physiology and pathology. *Essays Biochem*. 2020.
- 889 59. Gajer P, Brotman RM, Bai G, Sakamoto J, Schutte UM, Zhong X, et al. Temporal
890 dynamics of the human vaginal microbiota. *Sci Transl Med*. 2012;4(132):132ra52.
- 891 60. Witkin SS, Mendes-Soares H, Linhares IM, Jayaram A, Ledger WJ, Forney LJ. Influence
892 of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix
893 metalloproteinase inducer: implications for protection against upper genital tract infections.
894 *MBio*. 2013;4(4).
- 895 61. Edwards VL, Smith SB, McComb EJ, Tamarelle J, Ma B, Humphrys MS, et al. The
896 cervicovaginal microbiota-host interaction modulates *Chlamydia trachomatis* infection. *mBio*.
897 2019;10(4).
- 898 62. Petrova MI, Reid G, Vaneechoutte M, Lebeer S. *Lactobacillus iners*: Friend or Foe?
899 *Trends Microbiol*. 2017;25(3):182-91.
- 900 63. Troisi J, Sarno L, Landolfi A, Scala G, Martinelli P, Venturella R, et al. Metabolomic
901 Signature of Endometrial Cancer. *J Proteome Res*. 2018;17(2):804-12.
- 902 64. Vettukattil R, Hetland TE, Florenes VA, Kaern J, Davidson B, Bathen TF. Proton
903 magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions:
904 chemotherapy-related effects and comparison with malignant mesothelioma and breast
905 carcinoma. *Hum Pathol*. 2013;44(9):1859-66.
- 906 65. Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, et al.
907 Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic
908 Biomarkers of Ovarian High-Grade Serous Carcinomas. *Cancer Res*. 2016;76(4):796-804.
- 909 66. Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone
910 metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease.
911 *Nat Med*. 2015;21(3):263-9.
- 912 67. Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the NLRP3
913 inflammasome in cancer. *Mol Cancer*. 2018;17(1):158.
- 914 68. Kovachev S. Defence factors of vaginal lactobacilli. *Crit Rev Microbiol*. 2018;44(1):31-9.
- 915 69. McGroarty JA, Tomczek L, Pond DG, Reid G, Bruce AW. Hydrogen peroxide
916 production by *Lactobacillus* species: correlation with susceptibility to the spermicidal compound
917 nonoxynol-9. *J Infect Dis*. 1992;165(6):1142-4.
- 918 70. Hertelendy J, Reumuth G, Simons D, Stoppe C, Kim BS, Stromps JP, et al. Macrophage
919 migration inhibitory factor - a favorable marker in inflammatory diseases? *Curr Med Chem*.
920 2018;25(5):601-5.
- 921 71. Campisciano G, Zanotta N, Licastro D, De Seta F, Comar M. In vivo microbiome and
922 associated immune markers: New insights into the pathogenesis of vaginal dysbiosis. *Sci Rep*.
923 2018;8(1):2307.

- 924 72. Dabee S, Barnabas SL, Lennard KS, Jaumdally SZ, Gamiieldien H, Balle C, et al.
925 Defining characteristics of genital health in South African adolescent girls and young women at
926 high risk for HIV infection. *PLoS One*. 2019;14(4):e0213975.
- 927 73. Cheng RJ, Deng WG, Niu CB, Li YY, Fu Y. Expression of macrophage migration
928 inhibitory factor and CD74 in cervical squamous cell carcinoma. *Int J Gynecol Cancer*.
929 2011;21(6):1004-12.
- 930 74. Guo P, Wang J, Liu J, Xia M, Li W, He M. Macrophage immigration inhibitory factor
931 promotes cell proliferation and inhibits apoptosis of cervical adenocarcinoma. *Tumour Biol*.
932 2015;36(7):5095-102.
- 933 75. Krockenberger M, Engel JB, Kolb J, Dombrowsky Y, Hausler SF, Kohrenhagen N, et al.
934 Macrophage migration inhibitory factor expression in cervical cancer. *J Cancer Res Clin Oncol*.
935 2010;136(5):651-7.
- 936 76. Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, et al.
937 Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female
938 genital tract. *Immunity*. 2015;42(5):965-76.
- 939 77. Balkwill F. Tumour necrosis factor and cancer. *Nat Rev Cancer*. 2009;9(5):361-71.
- 940 78. Doerflinger SY, Throop AL, Herbst-Kralovetz MM. Bacteria in the vaginal microbiome
941 alter the innate immune response and barrier properties of the human vaginal epithelia in a
942 species-specific manner. *J Infect Dis*. 2014;209(12):1989-99.
- 943 79. Gardner JK, Laniewski P, Knight A, Haddad LB, Swaims-Kohlmeier A, Herbst-Kralovetz
944 MM. Interleukin-36gamma is elevated in cervicovaginal epithelial cells in women with bacterial
945 vaginosis and in vitro after infection with microbes associated with bacterial vaginosis. *J Infect*
946 *Dis*. 2020;221(6):983-8.
- 947 80. Ilhan ZE, Łaniewski P, Tonachio A, Herbst-Kralovetz MM. Members of *Prevotella* genus
948 distinctively modulate innate immune and barrier functions in a human three-dimensional
949 endometrial epithelial cell model. *J Infect Dis*. 2020:accepted for publication.
- 950




Fig. 1







Fig. 2

Lactobacillus dominance


A. Receiver operating characteristics



B. Confusion matrix



C. Most predictive features



Metabolic signatures

- lipids
- other metabolites

Immunoproteomic signatures


- immune mediators, cancer biomarkers

* elevated in NLD group; otherwise reduced


Fig. 3

Vaginal pH

A. Receiver operating characteristics



B. Confusion matrix



C. Most predictive features






Fig. 4

Genital Inflammation

A. Receiver operating characteristics



B. Confusion matrix



C. Most predictive features







Fig. 5

A. *Lactobacillus* dominance**B. Vaginal pH****C. Genital inflammation****Fig. 6**